MétaCan
Menu
Back to cohort
Record W2950101483 · doi:10.1002/mdc3.12803

Second‐Generation Antisense Nucleotide Targeting Huntingtin Expression Found to Be Safe in Patients With Huntington's Disease

2019· article· en· W2950101483 on OpenAlexaff
Alex Medina Escobar, Verónica Bruno, Justyna R. Sarna

Bibliographic record

VenueMovement Disorders Clinical Practice · 2019
Typearticle
Languageen
FieldNeuroscience
TopicGenetic Neurodegenerative Diseases
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsHuntingtinMedicineHuntington's diseaseHuntingtin ProteinTrinucleotide repeat expansionInternal medicineClinical endpointDiseasePolyglutamine tractChoreaPharmacologyOncologyClinical trialGeneticsBiologyGeneAllele

Abstract

fetched live from OpenAlex

Huntington's disease (HD) is a neurodegenerative autosomaldominant disorder caused by CAG trinucleotide repeat expansion in the huntingtin gene (HTT).HD is characterized by progressive neuropsychiatric, cognitive, and motor symptoms and is the most common cause of inherited chorea.Even though the HTT gene was identified more than one-quarter of a century ago, there are no disease-modifying therapies that prevent disease onset or slow its progression.1 Recent research efforts have focused on directly targeting the genetic abnormality.Recently, Tabrizi and colleagues have studied the effects of intrathecal administration of a secondgeneration antisense nucleotide, to inhibit messenger RNA, and therefore reduce huntingtin concentration levels. 2 Earlier research demonstrated that decreasing the levels of HTT in transgenic animal models and nonhuman primates with HTTlowering agents was feasible and safe.3 Forty-six eligible patients between 25 and 65 years of age with early HD, further defined as having ≥36 CAG repeats and a clinical stage 1, were randomized (3:1) into five different dose groups (10, 30, 60, 90, or 120 mg) in an ascending dose design to receive four intrathecal boluses at 4-week intervals of IONIS-HTTRx versus placebo.The primary endpoint was to evaluate safety of the drug.Secondary endpoints included cerebrospinal fluid (CSF) pharmacokinetics as well as plasma pharmacodynamics in addition to identifying its effect on concentration levels of HTT, neurofilament light protein in the CSF, ventricular volume, and the composite cognitive score on the Huntington's Disease Cognitive Assessment Battery.IONIS-HTTRx was found to be safe.Adverse events in both treatment and placebo groups were frequent (reported in 98% of patients), but were mild or moderate and deemed unrelated to direct effects of the drug.The most frequent adverse events were related to the intrathecal administration, including discomfort associated with the lumbar puncture as well as, postdural puncture headache.Serious adverse events were not reported, and no discontinuations or deaths occurred.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.318
Teacher spread0.289 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueMovement Disorders Clinical PracticeSame topicGenetic Neurodegenerative DiseasesFrench-language works237,207